Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.
作者信息
Yang Xin, Li Xiang, Zhang Yue-Lin, Zhang Sheng-Nan, Zhang Miao, Sun Chong, Yang Li, Liu Hong-Min, Yuan Shuo
机构信息
Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
出版信息
Future Med Chem. 2025 Jan;17(2):143-147. doi: 10.1080/17568919.2024.2444865. Epub 2024 Dec 23.
Abstract
摘要
相似文献
1
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.靶向不可成药蛋白KRAS用于癌症治疗：新机遇与挑战
Future Med Chem. 2025 Jan;17(2):143-147. doi: 10.1080/17568919.2024.2444865. Epub 2024 Dec 23.
2
Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.靶向“不可成药”的KRAS：胰腺癌治疗的突破、挑战与机遇
Cancer Biol Med. 2025 Jul 7. doi: 10.20892/j.issn.2095-3941.2025.0122.
3
Differential Response and Resistance to KRAS-Targeted Therapy.对KRAS靶向治疗的差异反应与耐药性。
Mol Carcinog. 2025 Jul;64(7):1135-1148. doi: 10.1002/mc.23908. Epub 2025 Apr 21.
4
"Undruggable KRAS": druggable after all.“不可成药的KRAS”：终究是可成药的。
Genes Dev. 2025 Jan 7;39(1-2):132-162. doi: 10.1101/gad.352081.124.
5
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?KRAS 突变型癌症中的精准免疫调节：拼图的最后一块？
J Exp Clin Cancer Res. 2025 Jul 3;44(1):189. doi: 10.1186/s13046-025-03444-1.
6
Targeting KRAS mutant cancers: from druggable therapy to drug resistance.靶向 KRAS 突变型癌症：从可用药治疗到耐药性。
Mol Cancer. 2022 Aug 4;21(1):159. doi: 10.1186/s12943-022-01629-2.
7
Targeting KRAS Mutation: Development of effective strategies to overcome drug resistance and limited efficacy.靶向KRAS突变：开发克服耐药性和有限疗效的有效策略。
Eur J Med Chem. 2025 Sep 15;294:117718. doi: 10.1016/j.ejmech.2025.117718. Epub 2025 May 12.
8
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的表皮生长因子受体（EGFR）抑制剂
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
9
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.靶向胰腺癌中的KRAS：新兴治疗策略
Adv Cancer Res. 2023;159:145-184. doi: 10.1016/bs.acr.2023.02.004. Epub 2023 Mar 9.
10
Insights into direct KRAS inhibition strategies for cancer treatment.癌症治疗中直接抑制KRAS策略的见解。
Future Med Chem. 2024;16(22):2411-2429. doi: 10.1080/17568919.2024.2424149. Epub 2024 Nov 21.
本文引用的文献
1
Targeting cancer with small-molecule pan-KRAS degraders.用小分子泛 KRAS 降解剂靶向癌症。
Science. 2024 Sep 20;385(6715):1338-1347. doi: 10.1126/science.adm8684. Epub 2024 Sep 19.
2
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.KRASG12C抑制剂IBI351单药治疗晚期非小细胞肺癌患者的疗效和安全性：一项2期关键研究的结果
J Thorac Oncol. 2024 Dec;19(12):1630-1639. doi: 10.1016/j.jtho.2024.08.005. Epub 2024 Aug 9.
3
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.HRS-4642 的抗肿瘤疗效及其与蛋白酶体抑制联合应用于 KRAS G12D 突变型癌症的潜力。
Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8. doi: 10.1016/j.ccell.2024.06.001. Epub 2024 Jun 27.
4
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS Inhibitor.MK-1084 的发现：一种口服生物利用度和低剂量 KRAS 抑制剂。
J Med Chem. 2024 Jul 11;67(13):11024-11052. doi: 10.1021/acs.jmedchem.4c00572. Epub 2024 Jun 26.
5
Targeting KRAS in cancer.针对癌症中的 KRAS 靶点。
Nat Med. 2024 Apr;30(4):969-983. doi: 10.1038/s41591-024-02903-0. Epub 2024 Apr 18.
6
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.RAS 驱动型癌症中 RMC-6236 抑制 RAS-GTP 的转化和治疗评估。
Cancer Discov. 2024 Jun 3;14(6):994-1017. doi: 10.1158/2159-8290.CD-24-0027.
7
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.索托拉西布是一种泛 RASG12C 抑制剂，能够驱动 NRASG12C 癌症的临床反应。
Cancer Discov. 2024 May 1;14(5):727-736. doi: 10.1158/2159-8290.CD-23-1138.
8
Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.RAS 靶向治疗策略的进展：从小分子抑制剂到蛋白水解靶向嵌合体。
Med Res Rev. 2024 Mar;44(2):812-832. doi: 10.1002/med.21993. Epub 2023 Nov 27.
9
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS Inhibitors.含氘亚甲基链接的多取代吡啶并[4,3-]嘧啶类似物的设计、合成及作为有效 KRAS 抑制剂的药理学评价。
J Med Chem. 2023 Nov 23;66(22):15524-15549. doi: 10.1021/acs.jmedchem.3c01724. Epub 2023 Nov 3.
10
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.索托拉西布联合帕尼单抗治疗携带 G12C 突变的难治性结直肠癌。
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
Zotero 插件